On Monday, it was announced that Amgen's cholesterol-lowering drug, Repatha, was found to decrease the risk of death by 20% in a clinical trial involving over 12,000 at-risk individuals. The medication, considered one of Amgen's top revenue generators, showed promising results in reducing mortality rates among high-risk patients.